Search Results - "Berdeja, J G"

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2‐YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE‐1 STUDY by Lin, Y., Martin, T., Berdeja, J. G., Jakubowiak, A., Agha, M., Cohen, A. D., Deol, A., Htut, M., Lesokhin, A., Munshi, N. C., O'Donnell, E., Jackson, C. C., Yeh, T.‐M., Banerjee, A., Zudaire, E., Madduri, D., Zhou, C., Pacaud, L., Usmani, S. Z., Jagannath, S.

Get full text

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE‐1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE‐CLASS EXPOSED MULTIPLE MYELOMA by Weisel, K., Mateos, M.‐V., Vincent, L., Martin, T., Berdeja, J. G., Jakubowiak, A., Jagannath, S., Lin, Y., Thilakarathne, P., Ghilotti, F., Diels, J., Haefliger, B., Hague, C., Gonzalez, A., Schecter, J. M., Gries, K. S., Strulev, V., Nesheiwat, T., Pacaud, L., Einsele, H., Moreau, P.

Get full text

S182: TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL‐1 by Minnema, M. C., Krishnan, A., Berdeja, J. G., Oriol, A., Donk, N. W., Rodríguez‐Otero, P., Morillo, D., Mateos, M.‐V., Costa, L. J., Caers, J., Vishwamitra, D., Ma, J., Yang, S., Hilder, B. W., Tolbert, J., Goldberg, J. D., Chari, A.

Get full text

P10: TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL‐1 by Donk, N. W. C. J, Minnema, M C, Berdeja, J G, Oriol, A, Krishnan, A, Rodríguez‐Otero, P, Askari, E, Mateos, M, Costa, L. J, Verona, R, Ma, J, Girgis, S, Yang, S, Hilder, B. W, Russell, J, Goldberg, J. D, Chari, A

Get full text

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS by JG Berdeja, AY Krishnan, A Oriol, NWV Donk, P Rodríguez-Otero, E Askari, M Mateos, MC Minnema, LJ Costa, R Verona, BW Hilderq, S Girgisq, T Prior, JS Russell, JD Goldberg, A Chari

“…Objectives: Patients with MM continue to relapse on current therapies, stressing the need for new immunotherapy targets. GPRC5D is an orphan receptor that is…”
Get full text

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA by SZ Usmani, JG Berdeja, A Jakubowiak, M Agha, AD Cohen, D Madduri, P Hari, T Yeh, Y Olyslager, A Banerjee, CC Jackson, A Allred, E Zudaire, W Deraedt, X Wu, L Pacaud, M Akram, Y Lin, T Martin, S Jagannath

“…Objectives: CARTITUDE-1 (NCT03548207) is a phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a chimeric antigen receptor T cell (CAR-T)…”
Get full text

B05: RESULTS FROM A META‐ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA by Gay, F, Berdeja, JG, De Stefano, V, Hari, P, Hooper, B, Haltner, A, Kumar, S, Martin, T, Mateos, M‐V, Moreau, P, Rosta, E, Samjoo, IA, Usmani, SZ, Weisel, K, Jackson, CC, Olyslager, Y, Schecter, JM, Vogel, M, Garrett, A, Lee, S, Nesheiwat, T, Pacaud, L, Zhou, C, Valluri, S, Costa, LJ, Lin, Y

Get full text

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma by Richardson, Paul G., Trudel, Suzanne, Popat, Rakesh, Mateos, María-Victoria, Vangsted, Annette J., Ramasamy, Karthik, Martinez-Lopez, Joaquín, Quach, Hang, Orlowski, Robert Z., Arnao, Mario, Lonial, Sagar, Karanes, Chatchada, Pawlyn, Charlotte, Kim, Kihyun, Oriol, Albert, Berdeja, Jesus G., Rodríguez Otero, Paula, Casas-Avilés, Ignacio, Spirli, Alessia, Poon, Jennifer, Li, Shaoyi, Gong, Jing, Wong, Lilly, Lamba, Manisha, Pierce, Daniel W., Amatangelo, Michael, Peluso, Teresa, Maciag, Paulo, Katz, Jessica, Pourdehnad, Michael, Bahlis, Nizar J.

“…Oral mezigdomide is a cereblon-modifying agent that results in degradation of transcription factors essential for myeloma cell survival. Given with…”
Get full text

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma by Berdeja, Jesus G, Hart, Lowell L, Mace, Joseph R, Arrowsmith, Edward R, Essell, James H, Owera, Rami S, Hainsworth, John D, Flinn, Ian W

“…The purpose of this study was to assess the safety and efficacy of the combination of panobinostat and carfilzomib in patients with relapsed/refractory…”
Get full text

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma by Krishnan, A, Kapoor, P, Palmer, J M, Tsai, N-C, Kumar, S, Lonial, S, Htut, M, Karanes, C, Nathwani, N, Rosenzweig, M, Sahebi, F, Somlo, G, Duarte, L, Sanchez, J F, Auclair, D, Forman, S J, Berdeja, J G

“…In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32…”
Get full text

New approaches to blood and marrow transplantation for patients with low-grade lymphomas by Berdeja, Jesús G, Flinn, Ian W

“…Low-grade lymphomas are generally considered incurable diseases with current standard therapies. Blood or marrow transplantation may be the exception…”
Get full text

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group by Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, Richardson, Paul G

“…This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple…”
Get full text

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma by Rowinsky, Eric K., Paner, Agne, Berdeja, Jesus G., Paba-Prada, Claudia, Venugopal, Parameswaran, Porkka, Kimmo, Gullbo, Joachim, Linder, Stig, Loskog, Angelica, Richardson, Paul G., Landgren, Ola

“…Summary This phase 1 study sought to characterize the safety, tolerability, and pharmacokinetic behavior of VLX1570, a small molecule inhibitor of the…”
Get full text

Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM) by Berdeja, J. G., Ailawadhi, S., Weitman, S. D., Zildjian, S., O'Leary, J. J., O'Keeffe, J., Guild, R., Whiteman, K., Chanan-Khan, A. A. A.

“…Abstract only…”
Get full text

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results by Richardson, Paul G., Bensinger, William I., Huff, Carol Ann, Costello, Caitlin L., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Siegel, David S., Lebovic, Daniel, Jagannath, Sundar, Laubach, Jacob P., Stockerl‐Goldstein, Keith E., Kwei, Long, Clow, Fong, Elias, Laurence, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, Vij, Ravi

“…Summary Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is a…”
Get full text

Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma by Berdeja, J.G, Lin, Y, Raje, N, Siegel, D, Munshi, N, Turka, A, Lam, L.P, Quigley, M.T, Kochenderfer, J.N

“…Introduction: Chimeric antigen receptor (CAR) T cell therapies have demonstrated robust and sustained clinical responses in several hematologic malignancies…”
Get full text

Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma by Berdeja, Jesüs G., Jones, Richard J., Zahurak, Marianna L., Piantadosi, Steven, Abrams, Ross A., Borowitz, Michael J., Vogelsang, Georgia B., Noga, Stephen J., Ambinder, Richard F., Flinn, Ian W.

“…PURPOSE: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL). PATIENTS AND METHODS: Thirty-five…”
Get full text

Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically by PITMAN, Sean D, QIN HUANG, ZUPPAN, Craig W, ROWSELL, Edward H, CAO, Jeffrey D, BERDEJA, Jesus G, WEISS, Lawrence M, JUN WANG

“…Although Hodgkin lymphoma-like posttransplantation lymphoproliferative disorder (HL-like PTLD) has been grouped with classic Hodgkin lymphoma type PTLD…”
Get full text

Immunotherapy of lymphoma: update and review of the literature by Berdeja, Jesús G

“…PURPOSEThe therapeutic options for treating patients with lymphoma have dramatically expanded with the advent of immune-based treatments. While monoclonal…”
Get full text